New integrations expand Rain's multi-chain support, enabling partners to easily launch stablecoin-powered card programs across even more blockchains simultaneously Rain, the global card issuing platform powered by stablecoins, today announced native support for Solana, Tron, and Stellar, expanding its mission to build modern financial infrastructure that is more accessible, programmable, and global. With these integrations, […]

Intensity Therapeutics, Inc. (“Intensity”or “the Company”) (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, announces that the Company will be presenting a Trials in Progress poster outlining its Phase 3 INVINCIBLE-3 clinical

Scope Technologies Corp. (CSE: SCPE) (OTCQB: SCPCF) (FSE: VN8) (“Scope Technologies” or the “Company”) provides an update on development of a comprehensive redesign of its public-facing product site for its QSE Group product website. The revised site is being tailored to align with QSE's focus on usability, improved product accessibility, and integration with ongoing user

— AI-Powered Legislative Insights: CODIT's Global Evidence-Based Policy Institute strengthens policy research and strategy CODIT, an AI-powered leading GovTech firm, has launched a policy monitoring platform developed to support the upcoming 2025 Asia-Pacific Economic Cooperation (APEC) Summit. The platform is intended to assist a wide range of stakeholders by delivering real-time updates on key policy

RonaTherapeutics, a global leading RNA therapy company, today announced preclinical data for its self-developed RNA interference (RNAi) therapy RN026 at the National Lipid Association (NLA) Annual Scientific Sessions.Preclinical studies revealed that the therapy, targeting lipoprotein(a) (Lp(a))-an independent risk factor for cardiovascular diseases-achieved a 99% reduction in Lp(a) with potential annual dosing regimen innon-human primate (NHP)

Meaningful efficacy observed in slow-progressor subgroup; NfL biomarker improvements support potential for accelerated regulatory pathway Neuronata-R®, an autologous bone marrow-derived mesenchymal stem cell (MSC) therapy for amyotrophic lateral sclerosis (ALS), has demonstrated meaningful efficacy signals in a subgroup of participants with slow disease progression in its recently completed Phase 3 trial. The therapy also showed

Demonstrating commitment to continuous performance improvement for delivery and services Alpha Omega, a leading provider of AI-driven modernization and digital transformation solutions to the federal government, announced today that it has been appraised at Level 5 of ISACA's Capability Maturity Model Integration for Development and Services (CMMI-DEV ML5, CMMI-SVC ML5).The appraisal was performed by Software

Thirteen funded projects will increase the native plant supply to help restore wildlife habitats This spring, WWF-Canada is scaling up an initiative to help restore ecosystems across Canada by increasing the native plant seed supply. The organization awarded grants to 13 First Nations, organizations and businesses in five provinces to support the establishment and expansion

Vaxart's Founder and Chief Scientific Officer Provides Video Update to Stockholders GlobeNewswire May 29, 2025 Dr. Sean Tucker, Founder and CSO of Vaxart, Urges Stockholders to Vote FOR Reverse Stock Split Proposal by 11:59 p.m. Eastern Time on June 1, 2025 Company Corrects Record on Common Misconceptions Regarding the Reverse Stock Split Proposal SOUTH SAN

(Other OTC:QEPC),(OTC US:QEPC), BOCA RATON, Fla., May 29, 2025 (GLOBE NEWSWIRE) — Q.E.P. CO., INC. (OTCQX: QEPC) (the “Company” or “QEP”) today reported its financial results for the full fiscal year ended February 28, 2025. These results follow the completion of a portfolio transformation in fiscal 2024, which included the divestiture of the Company's Harris